Abstract

Hyponatraemia is the most common electrolyte anomaly and is associated with significant morbidity and mortality. PatieRents with severe hyponatraemia often present to acute medical units with non-specific symptoms which can progress to overt neurological manifestations. There are many causes of hyponatriaemia, the most common being drug-induced causes, particularly thiazide diuretics, and the Syndrome of Inappropriate ADH Secretion (SIADH). Initial assessment should include a careful evaluation of the patient’s volume status, which helps to identify the most likely cause. This article utilises a recent case which presented to our AMU to illustrate the importance of a careful and systematic assessment of patients presenting to hospital with hyponatraemia. The new vasopressin receptor antagonists are explored as an option for the management of severe hyponatraemia.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

Referenes

1. Anderson RJ, Chung HM, Kluge R, et al; Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985; 102(2):164-8.
2. Mittal R, Sheftel H, Demssie Y; Management of hyponatraemia. Br J Hosp Med (Lond). 2011; 72(2):22-5.
3. Helwig FC, Schutz CB, Curry DE; Water intoxication. Report of a fatal case, with clinical, pathologic and experimental studies. JAMA. 1935; 104:1539-75.
4. Arieff AI. Hyponatremia, convulsions, respiratory arrest and permanent brain damage after elective surgery in healthy women. N Engl J Med.
   1986; 314:1529-35.
5. Moritz ML, Ayus JC, The pathophysiology and treatment of hyponatraemic encephalopathy: An update. Nephrology Dialysis Transplantation. 2003; 18 (12): 2486.
6. Sterns RH, Nigwekar SU, Hix JK; The treatment of hyponatremia. Semin Nephrol. 2009; 29(3):282-99.
7. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008, 48(3):1002-1010.
8. Lindsay A. Profound hyponatraemia in cirrhosis: A Case Report. Cases Journal 2010, 3:77.
9. Stephen RG, Hyponatremia and outcomes in patients with heart failure. Heart. 2012; 98:24 1761-62
10. Thompson TJ, Crowley RK. Hyponatraemia. J R Coll Physicians. 2009 39:154-7
11. Woo KH, Cho MH, Kim JK, et al. A Case of hyponatremia in hypothyroidism. Korean J Nephrol. 2007; 26(4):455-459.
12. Sterns, RH. Overview of the treatment of hyponatremia. In: UpToDate, Emmett, M (Ed), UpToDate, Rochester, USA. 2013.
13. Narayen G, Mandal SN. Vasopressin receptor antagonists and their role in clinical medicine. Indian J Endocrinol Metab. 2012; 16:183-191.
14. Schrier RW, Gross P, Gheorgiade M et al. Tolvaptan, a selective oral vasopressin V2- receptor antagonist for hyponatremia. N Engl J Med.
    2006; 355:2099–112.
15. Copeland PM. Diuretic abuse and central pontine myelinolysis. Psychotherapy and Psychosomatics. 1989; 52(1-3):101-5.
16. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatraemia, review and analysis of 129 reported patients. Clinical
    commentary. Chest. 1993; 103:601-06.
17. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008. 52:144-153.
18. Fourlanos S, Greenberg P. Managing drug-induced hyponatraemia in adults. Aust Prescr. 2003. 26:114-7.